|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.34 | 89.43 | 104.26 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
314.65
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
(Rs. in Million) | Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Audited / UnAudited | UnAudited | UnAudited | UnAudited | Audited | Net Sales | 5,628.00 | 5,187.00 | 5,132.00 | 5,067.00 | Total Expenditure | 4,915.00 | 4,515.00 | 4,412.00 | 5,507.00 | PBIDT (Excl OI) | 713.00 | 672.00 | 720.00 | -440.00 | Other Income | 485.00 | 696.00 | 360.00 | 640.00 | Operating Profit | 1,198.00 | 1,368.00 | 1,080.00 | 200.00 | Interest | 560.00 | 550.00 | 483.00 | 481.00 | Exceptional Items | 0 | -52.00 | 197.00 | 18,536.00 | PBDT | 638.00 | 766.00 | 794.00 | 18,255.00 | Depreciation | 309.00 | 306.00 | 298.00 | 294.00 | Profit Before Tax | 329.00 | 460.00 | 496.00 | 17,961.00 | Tax | 89.00 | 113.00 | 30.00 | -147.00 | Provisions and contingencies | 0 | 0 | 0 | 0 | Profit After Tax | 240.00 | 347.00 | 466.00 | 18,108.00 | Extraordinary Items | 0 | 0 | 0 | 0 | Prior Period Expenses | 0 | 0 | 0 | 0 | Other Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | Net Profit | 240.00 | 347.00 | 466.00 | 18,108.00 | Equity Capital | 6,003.00 | 6,003.00 | 6,003.00 | 6,003.00 | Face Value (IN RS) | 5 | 5 | 5 | 5 | Reserves | | | | | Calculated EPS | 0.20 | 0.29 | 0.39 | 15.08 | Calculated EPS (Annualised) | 0.80 | 1.16 | 1.55 | 60.33 | No of Public Share Holdings | 472,575,824.00 | 472,575,824.00 | 472,575,824.00 | 472,575,824.00 | % of Public Share Holdings | 39.36 | 39.36 | 39.36 | 39.36 | | | | | | PBIDTM% (Excl OI) | 12.67 | 12.96 | 14.03 | -8.68 | PBIDTM% | 21.29 | 26.37 | 21.04 | 3.95 | PBDTM% | 11.34 | 14.77 | 15.47 | 360.27 | PBTM% | 5.85 | 8.87 | 9.66 | 354.47 | PATM% | 4.26 | 6.69 | 9.08 | 357.37 | | Notes | Notes | Notes | Notes |
|
|
|
|
|
|